MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported progress on its pivotal Phase 3 trial in early Alzheimer’s disease while posting improved second-quarter financial results and expanding its intellectual property protections.
The company now has 76 U.S. clinical sites secured for the trial, with 46 actively enrolling and the remainder expected to begin soon. To date, more than 400 patients have been screened, with 38 receiving buntanetap or placebo and nearly 200 others in screening. The screen failure rate remains in line with expectations at about 50%.
“In the past quarter, our efforts were centered on driving enrollment for the pivotal Phase 3 trial in early AD,” said President and CEO Maria Maccecchini, Ph.D. “We also reached other notable milestones, including presenting our latest scientific findings at AAIC 2025 and strengthening our global intellectual property protection by completing the transfer of all patent families to crystal buntanetap.”
Annovis is also advancing its Parkinson’s program, with additional updates expected as development continues. At the Alzheimer’s Association International Conference in July, the company presented four scientific posters detailing progress in its Alzheimer’s study and the pharmacokinetic profile of buntanetap.
On the business side, Annovis appointed Hui Liu as Director of Biostatistics in April to oversee the statistical integrity of clinical trial data. In June, the company hosted a webcast with a live Q&A to update stakeholders on Phase 3 progress. In August, it announced the successful transfer of all patent families to crystal buntanetap, securing comprehensive global protection for both the original and new drug forms.
Financially, Annovis ended the quarter with $17.1 million in cash and cash equivalents, up from $10.6 million at year-end 2024. R&D expenses declined to $5.2 million from $5.8 million a year earlier, while general and administrative costs fell to $1.1 million from $2.0 million. The company reported a net loss of $0.32 per share, compared to $0.44 in the same quarter last year.
With enrollment advancing and intellectual property protections in place, Annovis aims to complete recruitment for the Alzheimer’s study on schedule while positioning buntanetap for broader neurological applications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.